PsyBio Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020
Period Ending	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cost of Revenue	0.05	0.05	1.56	1.53
Gross Profit	-0.05	-0.05	-1.56	-1.53
Selling, General & Admin	2.01	3.39	4.73	1
Research & Development	0.15	0.39	0.62	0.05
Operating Expenses	2.59	4.44	7.48	4.9
Operating Income	-2.64	-4.49	-9.04	-6.44
Interest Expense	-0.01	-0.02	-	-
Interest & Investment Income	0.03	0.03	0.09	-
Currency Exchange Gain (Loss)	0.01	0.02	0.03	-
Other Non Operating Income (Expenses)	0.75	-0.25	-0.63	0
EBT Excluding Unusual Items	-1.86	-4.72	-9.55	-6.44
Gain (Loss) on Sale of Investments	0	-0.16	-0.06	-
Legal Settlements	-0.01	-0.01	-0.15	-
Other Unusual Items	-0.03	-	-1.26	-
Pretax Income	-1.9	-4.89	-11.02	-6.44
Net Income	-1.9	-4.89	-11.02	-6.44
Net Income to Common	-1.9	-4.89	-11.02	-6.44
Shares Outstanding (Basic)	120	112	107	32
Shares Outstanding (Diluted)	120	112	107	32
Shares Change (YoY)	6.14%	4.56%	238.46%	-
EPS (Basic)	-0.02	-0.04	-0.10	-0.20
EPS (Diluted)	-0.02	-0.04	-0.10	-0.20
EBITDA	-2.52	-4.34	-	-
D&A For EBITDA	0.11	0.15	-	-
EBIT	-2.64	-4.49	-9.04	-6.44

Updated Aug 30, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.